首页> 外文期刊>Jornal de Pediatria >Analysis of analgesic, antipyretic, and nonsteroidal anti-inflammatory drug use in pediatric prescriptions a??
【24h】

Analysis of analgesic, antipyretic, and nonsteroidal anti-inflammatory drug use in pediatric prescriptions a??

机译:小儿处方中止痛,解热和非甾体类抗炎药的使用情况分析

获取原文
           

摘要

OBJECTIVE: Data on clinical practice in pediatrics on the use of analgesic, antipyretic, and nonsteroidal anti-inflammatory drugs considering the best available evidence and regulatory-agency approved use are uncertain. This study aimed to determine the frequency of prescription of these drugs according to the best scientific evidence and use approved by regulatory agencies. METHODS: This was a cross-sectional study of 150 pediatric prescriptions containing analgesic, antipyretic, and nonsteroidal anti-inflammatory drugs, followed by interview with caregivers at 18 locations (nine private drugstores and nine Basic Health Units of the Brazilian Unified Health System). The assessed outcomes included recommended use or use with no contraindication, indications with benefit evidence, and health surveillance agency-approved use. Data were analyzed in electronic databases and the variables were summarized by simple frequency. RESULTS: A total of 164 analgesic, antipyretic, and nonsteroidal anti-inflammatory drugs were prescribed to 150 children aged 1-4 years (38.6%). Dipyrone was included in 82 (54.6%) and ibuprofen in 40 (26.6%) prescriptions. Non-recommended uses were identified in 15% of prescriptions and contraindicated uses were observed in 13.3%. Nimesulide (1.5%) is still prescribed to children younger than 12 years. The dose was incorrect in 74.3% of prescriptions containing dipyrone. Of the 211 reported clinical indications, 56 (26.5%) had no evidence of benefit according to the best available scientific evidence and 66 (31.3%) had indications not approved by the regulatory agencies. CONCLUSION: There are significant discrepancies between clinical practice and recommended use of analgesic, antipyretic, and nonsteroidal anti-inflammatory drugs in pediatrics.
机译:目的:考虑到可获得的最佳证据和监管机构批准的使用,目前尚无有关小儿镇痛,解热和非甾体抗炎药使用的临床实践数据。这项研究旨在根据最佳科学证据和监管机构批准的用途确定这些药物的处方频率。方法:这是一项横断面研究,涉及150种儿科处方,其中包含镇痛药,解热药和非甾体类抗炎药,然后在18个地点(巴西统一卫生系统的9个私人药房和9个基本卫生部门)与护理人员进行了访谈。评估结果包括推荐使用或无禁忌使用,有获益证据的适应症以及卫生监督机构批准的使用。在电子数据库中分析数据,并通过简单频率汇总变量。结果:150例1-4岁儿童中共使用了164种镇痛,解热和非甾体类抗炎药(38.6%)。在82(54.6%)和40布洛芬(26.6%)处方中包括双吡酮和布洛芬。在15%的处方中发现了非推荐用途,在13.3%中发现了禁忌用途。尼美舒利(1.5%)仍被处方用于12岁以下的儿童。 74.3%含有双嘧达隆的处方剂量不正确。根据现有的最佳科学证据,在211种已报告的临床适应症中,没有56例(26.5%)没有获益的证据,而有66例(31.3%)具有未经监管机构批准的适应症。结论:小儿临床实践与推荐使用镇痛,解热和非甾体类抗炎药之间存在显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号